

# Harmony Outcomes

Harmony Outcomes Investigators

02 October 2018

Dear colleague


## Harmony Outcomes Results

We are writing to inform you of the results of the Harmony Outcomes trial which was presented today at the European Association for the Study of Diabetes ([link](#)) and also published simultaneously in the Lancet ([link](#)). We are pleased to report that the trial achieved its primary objective of demonstrating non-inferiority for the primary composite MACE outcome (cardiovascular death, myocardial infarction and stroke) ( $p < 0.0001$ ). Not only that, albiglutide also demonstrated a statistically significant 22% reduction in MACE ( $p = 0.0006$ ). There were no new safety findings of concern.


We hope you are pleased with these findings and that these have made all your hard work worthwhile. Through your participation in Harmony Outcomes and the evidence generated, you have directly contributed to our understanding of the important role that GLP1 receptor agonists now have in the management of patients Type 2 diabetes mellitus and cardiovascular disease. A press release has been issued by GSK and Duke Clinical Research Institute.

Once more, we would like to sincerely thank you, your staff and your patients for making the Harmony Outcomes trial a success and for your valuable contribution to medical knowledge on this important topic/debate.


Yours sincerely



Prof McMurray  
Executive Committee Co-Chair



Prof Del Prato  
Executive Committee Co-Chair



Dr Janmohamed  
Executive Committee  
Sponsor Representative

On behalf of the Harmony Outcomes Executive Committee and GlaxoSmithKline R&D